The risks included above are not exhaustive. Other factors that could adversely affect the combined company's business and prospects are described in the filings made by Hologic and Gen-Probe with the SEC. Hologic and Gen-Probe expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based.
RECONCILIATION OF GAAP EPS AND NET INCOME TO NON-GAAP ADJUSTED EPS,
NET INCOME AND EBITDA
(In thousands, except earnings per share)
Three Months Ended
June 25, 2011EARNINGS PER SHAREGAAP earnings per share- Diluted $
0.14Adjustments to net income (as detailed below) 0.18Non-GAAP adjusted earnings per share- Diluted $
(1)NET INCOMEGAAP net income $
36,196Adjustments:Amortization of intangible assets 59,671Non-cash interest expense relating to convertible notes18,229Contingent consideration 3,790Acquisition-related costs652Other-than-temporary impairment loss on equity investments345Income tax effect of reconciling items(33,147)
(2)Non-GAAP adjusted net income$
85,736EBITDANon-GAAP adjusted net income$
85,736Interest expense, net, not adjusted above9,959Provision for income taxes41,375Depreciation expense17,482Adjusted EBITDA $
154,552EXPLANATORY NOTES:(1) Non-GAAP adjusted earnings per share was calculated based on 265,167 weighted average diluted shares outstanding.(2) To reflect an estimated annual effective tax rate of 32.6% o
|SOURCE Hologic, Inc.|
Copyright©2012 PR Newswire.
All rights reserved